Shaperon (Drug Discovery) Overview
- Year Founded
-
2008
- Status
-
Public
- Employees
-
45
- Stock Symbol
-
378800
- Investments
-
1
- Share Price
-
$1.54
- (As of Friday Closing)
Shaperon (Drug Discovery) General Information
Description
Shaperon Inc is a developer of innovative inflammasome inhibitors and nanobody therapeutics intended to develop novel treatments for various chronic inflammatory diseases, including atopic dermatitis, systemic inflammatory response syndrome, neuroinflammatory diseases, and chronic inflammation. It offers a range of drug candidates, including a gel-type atopic dermatitis drug for use in the treatment of systemic inflammatory response syndrome, neuroinflammatory diseases and for treating chronic inflammation. The company also provides immunotherapeutic products and a single-domain neutralizing antibody, enabling clients to improve patient's quality of life by developing safe and efficacious drugs and immunotherapies.
Contact Information
Website
www.shaperon.comCorporate Office
- 174-10, Jagok-ro, Gangnam-gu
- Gangnam ACE tower Suite 606
- Seoul, 03080
- South Korea
Corporate Office
- 174-10, Jagok-ro, Gangnam-gu
- Gangnam ACE tower Suite 606
- Seoul, 03080
- South Korea
Shaperon (Drug Discovery) Timeline
Shaperon (Drug Discovery) Stock Performance
As of 13-Nov-2026, Shaperon (Drug Discovery)’s stock price is $1.54. Its current market cap is $10.6M with 6.86M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.54 | $1.54 | $1.39 - $7.55 | $10.6M | 6.86M | 95.8K | -$1.50 |
Shaperon (Drug Discovery) Financials Summary
As of 30-Jun-2026, Shaperon (Drug Discovery) has a trailing 12-month revenue of $222K.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,602 | 34,092 | 57,890 | 47,880 |
| Revenue | 222 | 160 | 13 | 165 |
| EBITDA | (10,269) | (10,100) | (10,307) | (9,541) |
| Net Income | (10,910) | (10,911) | (10,922) | (9,487) |
| Total Assets | 18,910 | 19,358 | 13,092 | 19,406 |
| Total Debt | 5,083 | 188 | 191 | 334 |
Shaperon (Drug Discovery) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Shaperon (Drug Discovery) Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Shaperon (Drug Discovery) Patents
Shaperon (Drug Discovery) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026235539-A1 | Composition for preventing or treating diabetic foot disease, comprising taurodeoxycholic acid | Pending | 09-May-2025 | ||
| WO-2025023752-A1 | Composition for preventing or treating cardiopulmonary bypass-induced vasoplegic syndrome or systemic inflammatory response syndrome, containing taurodeoxycholic acid or pharmaceutically acceptable salt thereof as active ingredient | Inactive | 27-Jul-2023 | ||
| WO-2024248599-A1 | Single domain antibody against serpin a12 and use thereof | Inactive | 30-May-2023 | ||
| EP-4619546-A1 | Biomarkers for predicting the treatment efficacy of gpcr19 agonists in the treatment of atopic dermatitis and methods for treating subjects with such biomarkers | Pending | 15-Nov-2022 | ||
| EP-4619546-A4 | Biomarkers for predicting the treatment efficacy of gpcr19 agonists in the treatment of atopic dermatitis and methods for treating subjects with such biomarkers | Pending | 15-Nov-2022 | C12Q1/6883 |
Shaperon (Drug Discovery) Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Shaperon (Drug Discovery) Acquisitions (1)
Shaperon (Drug Discovery)’s most recent deal was a Merger/Acquisition with Needs Tech. The deal was made on 02-Jul-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Needs Tech | 02-Jul-2026 | Merger/Acquisition | Therapeutic Devices |
Shaperon (Drug Discovery) ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Shaperon (Drug Discovery) Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Hudson Therapeutics | Durham, NC | 2023 | |
| Needs Tech | Seoul, South Korea |
Shaperon (Drug Discovery) FAQs
-
When was Shaperon (Drug Discovery) founded?
Shaperon (Drug Discovery) was founded in 2008.
-
Where is Shaperon (Drug Discovery) headquartered?
Shaperon (Drug Discovery) is headquartered in Seoul, South Korea.
-
What is the size of Shaperon (Drug Discovery)?
Shaperon (Drug Discovery) has 45 total employees.
-
What industry is Shaperon (Drug Discovery) in?
Shaperon (Drug Discovery)’s primary industry is Drug Discovery.
-
Is Shaperon (Drug Discovery) a private or public company?
Shaperon (Drug Discovery) is a Public company.
-
What is Shaperon (Drug Discovery)’s stock symbol?
The ticker symbol for Shaperon (Drug Discovery) is 378800.
-
What is the current stock price of Shaperon (Drug Discovery)?
As of 13-Nov-2026 the stock price of Shaperon (Drug Discovery) is $1.54.
-
What is the current market cap of Shaperon (Drug Discovery)?
The current market capitalization of Shaperon (Drug Discovery) is $10.6M.
-
What is Shaperon (Drug Discovery)’s current revenue?
The trailing twelve month revenue for Shaperon (Drug Discovery) is $222K.
-
What is Shaperon (Drug Discovery)’s annual earnings per share (EPS)?
Shaperon (Drug Discovery)’s EPS for 12 months was -$1.50.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
